PriceTargets.com logo

Reviva Pharmaceuticals - RVPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $3.86
  • Forecasted Upside: 552.43%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$0.59 As of 12/4/2025 05:00 PM ET
▼ -0.0034 (-0.57%)

This chart shows the closing price for RVPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reviva Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVPH

Analyst Price Target is $3.86
▲ +552.43% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Reviva Pharmaceuticals in the last 3 months. The average price target is $3.86, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 552.43% upside from the last price of $0.59.

This chart shows the closing price for RVPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Reviva Pharmaceuticals. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2025Chardan CapitalUpgradeStrong-Buy
11/19/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$2.00
10/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$2.00
10/27/2025HC WainwrightLower TargetBuy ➝ Buy$11.00 ➝ $4.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/29/2025Chardan CapitalInitiated CoverageBuy$2.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/19/2025D. Boral CapitalLower TargetBuy ➝ Buy$3.00 ➝ $2.00
9/15/2025BenchmarkLower TargetSpeculative Buy ➝ Speculative Buy$14.00 ➝ $7.00
8/18/2025Roth CapitalReiterated RatingBuy ➝ Buy$7.00 ➝ $3.00
8/18/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$3.00
8/15/2025CitigroupReiterated RatingBuy ➝ Buy
8/15/2025Maxim GroupLower TargetBuy ➝ Buy$5.00 ➝ $2.00
6/27/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$3.00
6/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$3.00
5/20/2025D. Boral CapitalLower TargetBuy ➝ Buy$8.00 ➝ $3.00
4/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
4/1/2025D. Boral CapitalLower TargetBuy ➝ Buy$15.00 ➝ $8.00
1/22/2025HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $11.00
1/21/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
1/10/2025Roth CapitalUpgradeStrong-Buy
1/10/2025Maxim GroupUpgradeHold ➝ Buy$7.00
1/10/2025Roth MkmInitiated CoverageBuy$7.00
9/23/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
8/26/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$17.00 ➝ $17.00
8/16/2024Maxim GroupReiterated RatingBuy ➝ Hold
7/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
6/11/2024HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $14.00
5/28/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$17.00 ➝ $17.00
4/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
4/16/2024BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy$17.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
2/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$20.00
12/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00
10/31/2023HC WainwrightBoost TargetBuy ➝ Buy$10.00 ➝ $20.00
10/30/2023Roth MkmReiterated RatingBuy ➝ Buy$12.00
9/20/2023Roth CapitalReiterated RatingBuy
9/20/2023Roth MkmInitiated CoverageBuy$12.00
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00
6/8/2023BenchmarkInitiated CoverageBuy$17.00
5/3/2023Maxim GroupBoost Target$10.00 ➝ $18.00
4/4/2023HC WainwrightReiterated RatingBuy$20.00
1/25/2023HC WainwrightReiterated RatingBuy$10.00
11/1/2022Maxim GroupBoost TargetBuy$3.00 ➝ $10.00
11/1/2022Alliance Global PartnersInitiated CoverageBuy$16.00
1/24/2022HC WainwrightInitiated CoverageBuy$10.00
7/26/2021Maxim GroupInitiated CoverageBuy$10.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Reviva Pharmaceuticals logo
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Read More

Today's Range

Now: $0.59
Low: $0.59
High: $0.62

50 Day Range

MA: $0.55
Low: $0.30
High: $0.84

52 Week Range

Now: $0.59
Low: $0.25
High: $4.28

Volume

3,544,116 shs

Average Volume

3,698,027 shs

Market Capitalization

$68.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Reviva Pharmaceuticals?

The following sell-side analysts have issued reports on Reviva Pharmaceuticals in the last year: Benchmark Co., Chardan Capital, Citigroup Inc., D. Boral Capital, HC Wainwright, Maxim Group, Roth Capital, Roth Mkm, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for RVPH.

What is the current price target for Reviva Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Reviva Pharmaceuticals in the last year. Their average twelve-month price target is $3.86, suggesting a possible upside of 552.4%. Benchmark Co. has the highest price target set, predicting RVPH will reach $7.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $2.00 for Reviva Pharmaceuticals in the next year.
View the latest price targets for RVPH.

What is the current consensus analyst rating for Reviva Pharmaceuticals?

Reviva Pharmaceuticals currently has 1 sell rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RVPH.

What other companies compete with Reviva Pharmaceuticals?

Other companies that are similar to Reviva Pharmaceuticals include Humacyte, Alpha Teknova, Puma Biotechnology, Zura Bio and Cabaletta Bio. Learn More about companies similar to Reviva Pharmaceuticals.

How do I contact Reviva Pharmaceuticals' investor relations team?

Reviva Pharmaceuticals' physical mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The company's listed phone number is (408) 501-8881 and its investor relations email address is ir.revivapharma.com. The official website for Reviva Pharmaceuticals is www.revivapharma.com. Learn More about contacing Reviva Pharmaceuticals investor relations.